Search Results for “EC” – Page 222 – media

New Analytical Tool Could Replace Traditional Biopsies with Liquid Biopsies for Disease Diagnosis

Biopsies are important clinical tools used to diagnose various diseases or monitor tissues for abnormal growth or transplant rejection. Typically, this involves removing tissue samples from the body for closer examination, which can be invasive depending on the tissue required. Researchers have developed a new analytical method that could enable the use of “liquid biopsies” as an alternative to traditional biopsies for certain patients or diseases. This new tool, developed by researchers from Vanderbilt University’s School of Medicine Basic Sciences (Nashville, TN, USA), is known as EV Fingerprinting, where EV stands for extracellular vesicles. EVs are membrane-bound particles filled with biologically active materials that play a crucial role in cell-cell communication in both health and disease. Although EVs have been studied since the 1980s, their origins and functions have not been fully defined. Research on EVs has intensified over the last two decades, revealing their involvement in processes such as ...
- Source: drugdu
- 97
- July 19, 2024
FDA Grants Fast Track Designation to Abdera Therapeutics’ Treatment for Extensive-Stage Small Cell Lung Cancer

By Don Tracy, Associate Editor The novel therapy, ABD-147, uses advanced antibody engineering to deliver Actinium-225 to solid tumors expressing DLL3, a protein found on neuroendocrine tumors. The FDA has granted Fast Track Designation to Abdera Therapeutics’ ABD-147, a next-generation precision radiopharmaceutical therapy designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed following platinum-based chemotherapy. According to the company, ABD-147 implements advanced antibody engineering to deliver Actinium-225 to solid tumors expressing DLL3, which is a protein commonly found on neuroendocrine tumors but rarely expressed on the surface of normal cells or tissues.1 “Aggressive neuroendocrine cancers such as SCLC carry a poor prognosis and new treatment options are urgently needed,” said Lori Lyons-Williams, president, CEO, Abdera Therapeutics, in a press release. “These cancers have the most aggressive clinical course of any type of pulmonary tumor and often rapidly metastasize to other parts of the body. We are ...
- Source: drugdu
- 99
- July 19, 2024
Roche Weighs In With Encouraging Early Clinical Data for Oral GLP-1 Drug

Roche reported its oral GLP-1 agonist led to an average 6.1% weight loss at four weeks, according to preliminary results from part of a Phase 1 study. The small molecule comes from Roche’s $2.7 billion acquisition of Carmot Therapeutics last year. By Frank VinluanRoche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that keep the pharmaceutical giant in contention to bring patients a pill to tap into this increasingly popular mechanism for weight loss. The results reported Wednesday are from a Phase 1 test of CT-996, a once-daily pill designed to activate the GLP-1 receptor to treat type 2 diabetes and obesity. Roche said treatment of patients who are obese and do not have type 2 diabetes lost a placebo-adjusted average of 6.1% of body weight within ...
- Source: drugdu
- 79
- July 19, 2024
KCL leads first guidelines on immune monitoring for hard-to-treat blood cancer

Myelodysplastic syndromes are a group of blood cancers that currently affect more than 7,000 people in the UK King’s College London (KCL) has led the publication of first-in-their-kind guidelines that aim to standardise how clinicians measure the immune response of patients living with a hard-to-treat form of blood cancer. The new guidelines will help identify which patients could respond to certain types of therapies, as well as better categorise patients based on whether their immune response is autoimmune or autoinflammatory to determine the choice of therapy and clinical outcome. Affecting more than 7,000 people in the UK, myelodysplastic syndromes (MDS) are a group of blood cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells, causing them to die in the bone marrow or just after entering the bloodstream. Risks associated with MDS can include an increased likelihood of infections, anaemia, bleeding ...
- Source: drugdu
- 79
- July 19, 2024
German CDMO outlays $980m on GLP-1 manufacturing expansion

German contract development and manufacturing organisation (CDMO) Corden Pharma announced a €900m ($980m) investment to expand its diabetes drug manufacturing capabilities, as shortages persist around the world. The company declared that the investment would be used over the next three years to expand its peptide manufacturing capabilities at sites in Colorado, US, and Europe. The facilities will have a particular focus on GLP-1 peptide manufacturing, as the demand increases. In a 16 July press release, the company spoke of multiple long-term contracts worth more than €3bn with potential benefits. Last year, the company signed a major deal with Eli Lilly to manufacture the active pharmaceutical ingredient for its leading obesity drug Mounjaro (tirzepatide), as per a Reuters report. In January 2023, the company also shared the signing of a $1bn multi-year agreement to manufacture a large volume peptide with an undisclosed company. The latest investment will be used to construct ...
- Source: drugdu
- 72
- July 19, 2024
Revolution sets sights on Phase III trial for pan-RAS inhibitor

Revolution Medicine plans to kickstart a Phase III trial following positive data from a first-in-human study of its investigational KRAS inhibitor RMC-6236 in pancreatic cancer patients. In an investor deck released yesterday [15 July], the company outlined updated data from the Phase I trial (NCT05379985) that outlined responses from 127 patients with pancreatic ductal carcinoma (PDAC) who received between a dose of RMC-6236 ranging from 160mg to 300mg. Median progression-free survival was 8.1 months in patients with the KRAS G12X mutation, and 7.6 months in those who broadly have RAS-mutant tumours. Among participants who had at least three prior treatment regimens, the median progression-free survival was 4.2 months. Out of the 127 participants, 96% suffered from side effects. The most common were rashes, diarrhoea, nausea, and mouth sores. Those adverse events were deemed severe or medically significant in 28% of patients. The company had previously presented early Phase I data, ...
- Source: drugdu
- 71
- July 19, 2024
Interphex Japan

Organiser：Reed Exhibitions Time：July 9-11, 2025 address： 3-21-1 Ariake, Koto-ku, Tokyo 135-0063, Japan Exhibition hall：Tokyo Big Sight International Exhibition Center Product range: Biomaterials: Amplification Equipment, DNA Extraction Equipment, Proteome Extraction & Purification, DNA Analysis Equipment, Proteome Analysis Equipment, Nuclear Magnetic Resonance, Automated Workstations, Automatic Dispensers, Cell Analysis Equipment, Incubators, Refrigerators, Nutrient Media, Mixers, Pipettes, Assay Kits, Regenerative Medicine, Drug Development, Biomaterials, Biocontracting, Pharmaceutical Intermediates, Cosmetic Ingredients, Fine Chemicals, Additives, Excipients, Plant Extracts Instrumentation: Analytical Instruments, Laboratory Equipment & Accessories, Chemical Reagents Bioengineering: Bioprocesses, Biochemistry, Biotechnology & Products, Analytical Methods, Nanobiotechnology & Products; Optics & Technologies Bioinformatics & Services: Bioinformatics, Biotechnology Services Medical & Pharmaceutical Applications: Medicine & Pharmaceuticals, Biologics, Biosimilars, & Biobetters Environmental Applications: Environmental Biotechnology, Agricultural Applications, Agricultural Products/Plant Biotechnology, Animal Husbandry Pharmaceutical Excipients: Pharmaceutical Packaging Materials, Pharmaceutical Excipients, Pharmaceutical Adjuvants & Equipment; Excipients (Antimicrobial Preservatives, Antioxidants, Capsules/Encapsulation, Coating Agents, Colors & Dispersions, Drug Delivery Systems, Emulsifiers/Solvents, Flavors & Fragrances, ...
- Source: drugdu
- 102
- July 19, 2024
【EXPERT Q&A】What are the potential areas for improvement in the accuracy of medical equipment?

Drugdu.com expert’s response: The potential for improvement in the accuracy of medical equipment primarily manifests in the following aspects: I.Technological Advancement and Innovation 1.Genetic Testing and Analysis: By leveraging advanced genomic technologies, patient genetic information can be analyzed with greater precision, providing data support for the customization of personalized medical devices. This precise data analysis facilitates the devices’ better adaptation to individual patient differences. 2.Personalized Drug Delivery Systems: Developing delivery systems capable of precisely adjusting drug dosage and release rates based on patients’ genetic profiles and physiological states ensures the drugs’ effectiveness and safety within the body. 3.3D Printing Technology: Utilizing 3D printing to create patient-specific surgical models and prosthetics enhances surgical precision and personalization. For instance, printing prosthetics that perfectly match patients’ anatomical structures reduces surgical risks and improves recovery outcomes. 4.Real-time Physiological Monitoring: Developing medical devices capable of continuously and accurately monitoring patients’ physiological states, such as wearable ...
- Source: drugdu
- 87
- July 19, 2024
Innovative C. Difficile Diagnostic Test Provides Both GDH and Toxin Results within 30 Minutes

Clostridium difficile is a leading cause of hospital-acquired diarrhea and pseudomembranous colitis. Infections typically occur when antibiotics disrupt the normal gut flora. Toxigenic strains of C. difficile produce toxins A and B, which are responsible for the symptoms of the infection. Diagnosing C. difficile can be complex because it is possible to carry the bacteria without it producing disease-causing toxins. All strains of C. difficile produce glutamate dehydrogenase (GDH), making GDH testing a useful initial screen for the infection. However, additional tests are necessary since a GDH-positive result does not confirm if the strain is toxin-producing, which is necessary to determine if the patient has an active infection or is just a carrier. Now, a new test that provides results for both GDH and the toxins within approximately 30 minutes can help healthcare professionals accurately distinguish between active infection and colonization in a cost-effective and clinically relevant way. The C. ...
- Source: drugdu
- 66
- July 18, 2024
NIHR and Diabetes UK invest nearly £3m to prevent and treat diabetes distress

The National Institute for Health and Care Research (NIHR) and Diabetes UK have partnered, investing nearly £3m, to develop research to treat and prevent type 1 diabetes (T1D) distress. The new funding, awarded to Professor Jackie Sturt at King’s College London, will help to test a new programme known as ‘D-Stress’ to help tackle the overwhelming burden for adults living with the chronic condition. According to Diabetes UK, around 4.4 million people in the UK are living with diabetes, a metabolic disease characterised by elevated levels of blood glucose. Occurring when the pancreas does not produce insulin or makes very little insulin, T1D accounts for approximately 10% of diabetes cases in the UK and almost 50% of adults living with the condition experience high levels of diabetes distress. The new programme aims to deliver care within the NHS for the detection, prevention and management of T1D in adults and will ...
- Source: drugdu
- 71
- July 18, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.